AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
Dec 17, 2024
32883_dirs_2024-12-17_cef4d1fc-d710-42d2-b471-0a33e470dbb7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-12-09
Reporting Person: TacticGem LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-09 | Common Stock | J | 1433334 | — | Disposed | 0 | Direct |
Footnotes
F1: Tactic Gem, LLC distributed 611,079 shares to Gem Pharmaceuticals, LLC and 822,255 shares to Tactic Pharma, LLC for no consideration.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2